Tuesday, October 4, 2022


Biotechnology News Magazine

Unravel Biosciences Partners with TMA Precision Health to Advance Drug Treatment for Rett Syndrome into the Clinic

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Unravel Biosciences, Inc. (“Unravel”), a therapeutics company that spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University, seamlessly bridges target discovery with clinical efficacy to advance drugs for complex diseases, today announced a partnership with TMA Precision Health (“TMA”), a Startup Health platform for rare diseases, aimed at identifying rare Rett Syndrome patients for inclusion in Unravel’s first-in-human reformulated drug trial.

Unravel Biosciences will leverage TMA’s unique access to rare disease patients to pre-enrich its clinical trial enrollment and accelerate their work for this extremely rare condition that currently has no cure.

Rett Syndrome is a rare neurodevelopmental disorder that occurs primarily in girls and impacts the whole body, including cognitive and fine motor functions. The disorder is equally present worldwide and affects one in every 10,000 live births, making it challenging to find patients to participate in clinical trials. TMA’s database of patients from global sources makes it easier to locate the right patients and advance promising therapies through clinical development.

Unravel’s proprietary BioNAV™ platform combines network-based computational prediction, patient transcriptomic information, and a first-in-class unbiased Xenopus platform to decode, model, and develop new therapeutics for complex diseases. Unravel’s approach developed RVL001, a proprietary oral liquid formulation that improves clinically-relevant metrics and will be evaluated in rapid, data-rich clinical trials to de-risk uncovered drug targets.

“For us at TMA, this partnership is exactly the kind of work we set out to do: enabling companies like Unravel to more fully leverage their drug discovery platforms and power real change for patients without options,” said Joshua Resnikoff, MS, TMA Cofounder and CEO. “We’re incredibly proud to be a part of Unravel’s efforts by using our clinicogenomics database to help drive their clinical work forward.”

“Unravel Biosciences is thrilled to partner with TMA to power this first step to the clinic for RVL001. By integrating a clinical data-focused trial design with our computational drug and target discovery platform, this collaboration will accelerate and derisk drug development for Rett syndrome,” said Richard Novak, PhD, Unravel Cofounder and CEO. “TMA’s unique capabilities identifying orphan disease patient populations in global regions historically underrepresented in trials are directly aligned with our mission to rapidly bring effective treatments to patients in need.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine